Treatment Category Profile

Treatment Name:	Foretinib	Known as: Also Known As:	Foretinib GSK1363089, XL880
Treatment Type:	Multi-Targeted	Status:	FDA Approved (phase II)
GSK1363089 is a new chemical entity that inhibits multiple receptor tyrosine kinases (RTKs) with growth-promoting and angiogenic properties. It is a multikinase inhibitor of AXL, MET, and vascular endothelial growth factor receptors. It has recently demonstrated efficacy with Papillary Renal Cell Carcinoma.

   Articles related to this Treatment

	1 Small Study Shows 90% Benefit Rate in Papillary Kidney Cancer Medpage Today Sep 30, 2009